Skip to main content
. 2021 Jun 13;9(2):525–539. doi: 10.1007/s40487-021-00156-2

Fig. 4.

Fig. 4

Kaplan–Meier plots of OS for patients treated with a dacomitinib or b gefitinib based on PPI use groups. Red lines represent patients in the reference (non-PPI user) group, green lines represent the PPI user group, and blue lines represent patients in the extensive PPI user group. OS overall survival; PPI proton pump inhibitor